目的 探討腦脈泰膠囊聯(lián)合奧拉西坦注射液治療血管性癡呆的臨床療效。方法 選取2014年9月-2016年9月商丘市第五人民醫(yī)院神經(jīng)內(nèi)科收治的血管性癡呆患者108例，所有患者在隨機(jī)分組的原則下分成對照組和治療組，每組各54例。對照組靜脈滴注奧拉西坦注射液，4.0 g加入到5%葡萄糖溶液250 mL中，1次/d。治療組在對照組基礎(chǔ)上口服腦脈泰膠囊，2粒/次，3次/d。兩組均治療1個月。觀察兩組的臨床療效，比較兩組炎癥因子、認(rèn)知功能和日常生活質(zhì)量。結(jié)果 治療后，對照組和治療組的總有效率分別為68.52%、90.74%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清腫瘤壞死因子（TNF-α）、白細(xì)胞介素-6（IL-6）和C-反應(yīng)蛋白（CRP）水平均顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組MMSE評分和ADL評分均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的升高程度明顯優(yōu)于對照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 腦脈泰膠囊聯(lián)合奧拉西坦注射液治療血管性癡呆具有較好的臨床療效，可改善認(rèn)知功能和日常生活質(zhì)量，降低炎癥因子水平，具有一定臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Naomaitai Capsules combined with Oxiracetam Injection in treatment of vascular dementia. Methods Patients (104 cases) with vascular dementia in Department of Neurology of Shangqiu Fifth People's Hospital from September 2014 to September 2016 were randomly divided into control and treatment groups, and each group had 54 cases. Patients in the control group were iv administered with Oxiracetam Injection, 4.0 g added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Naomaitai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and inflammatory indexes, cognitive function, and quality of life in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 68.52% and 90.74%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of TNF-α, IL-6, and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, MMSE scores and ADL scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Naomaitai Capsules combined with Oxiracetam Injection has clinical curative effect in treatment of vascular dementia, and can improve cognitive function and quality of life and decrease the levels of inflammatory indexes, which has a certain clinical application value.